Flanvotumab, also known as IMC-20D7S, is a human monoclonal antibody designed for the treatment of melanoma.[1] It targets TYRP1.[2]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | HGF |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6470H9986N1714O2018S46 |
Molar mass | 145545.80 g·mol−1 |
(what is this?) (verify) |
Flanvotumab was developed by ImClone Systems, now owned by Eli Lilly.[2]
References
edit- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Flanvotumab" (PDF). American Medical Association.
- ^ a b "Flanvotumab". Adis Insight. Springer Nature Switzerland AG.